Fresenius Medical Care AG & Co. KGaA

  • WKN: 578580
  • ISIN: DE0005785802
  • Land: Deutschland

Nachricht vom 29.04.2019 | 16:50

Fresenius Medical Care AG & Co. KGaA: Release of a capital market information

Fresenius Medical Care AG & Co. KGaA / Announcement pursuant to Art.
5 para.
1 lit. b), para. 3 of Regulation (EU) No 596/2014 and Art. 2 para. 3 of
Delegated Regulation (EU) 2016/1052

29.04.2019 / 16:50
Dissemination of a Post-admission Duties announcement transmitted by DGAP -
a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


- Share buy-back - 7th Interim Report In the period from April 23, 2019 until and including April 26, 2019, a total of 192,031 shares were repurchased within the framework of the share buy-back programme of Fresenius Medical Care AG & Co. KGaA ('Fresenius Medical Care') announced on March 11, 2019 pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No 596/2014 and Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052. The purchase was carried out exclusively by a credit institution commissioned by Fresenius Medical Care via the XETRA trading platform on the Frankfurt Stock Exchange: Day of repurchase Aggregated volume in Weighted average share number of shares price in EUR 23.04.2019 18,812 70.5943 24.04.2019 45,423 71.4382 25.04.2019 109,175 71.9345 26.04.2019 18,621 72.2080 The total volume of shares repurchased within the framework of this share buy-back in the period from March 12, 2019 until and including April 26, 2019 therefore amounts to 3,561,768 shares. Detailed information on the transactions pursuant to Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052 is available on Fresenius Medical Care's website at www.freseniusmedicalcare.com under section Investors. Fresenius Medical Care AG & Co. KGaA represented by Fresenius Medical Care Management AG represented by its Management Board Bad Homburg v.d.H., April 29, 2019
29.04.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language: English Company: Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany Internet: www.freseniusmedicalcare.com End of News DGAP News Service

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Wirecard AG beauftragt unabhängige Prüfung

21. Oktober 2019, 07:40

Aktuelle Research-Studie

ad pepper media International N.V.

Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Hinzufügen

18. Oktober 2019